company background image
42C logo

iX Biopharma Catalist:42C Stock Report

Last Price

S$0.053

Market Cap

S$40.0m

7D

26.2%

1Y

-38.4%

Updated

27 Mar, 2024

Data

Company Financials

42C Stock Overview

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia.

42C fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

iX Biopharma Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for iX Biopharma
Historical stock prices
Current Share PriceS$0.053
52 Week HighS$0.10
52 Week LowS$0.035
Beta0.90
1 Month Change29.27%
3 Month Change17.78%
1 Year Change-38.37%
3 Year Change-75.35%
5 Year Change-76.96%
Change since IPO-90.54%

Recent News & Updates

Recent updates

Shareholder Returns

42CSG PharmaceuticalsSG Market
7D26.2%-0.7%1.6%
1Y-38.4%7.9%-4.4%

Return vs Industry: 42C underperformed the SG Pharmaceuticals industry which returned 7.9% over the past year.

Return vs Market: 42C underperformed the SG Market which returned -4.4% over the past year.

Price Volatility

Is 42C's price volatile compared to industry and market?
42C volatility
42C Average Weekly Movement13.1%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in SG Market14.3%
10% least volatile stocks in SG Market2.2%

Stable Share Price: 42C's share price has been volatile over the past 3 months.

Volatility Over Time: 42C's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of SG stocks.

About the Company

FoundedEmployeesCEOWebsite
2004n/aEddy Leehttps://www.ixbiopharma.com

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia. The company operates through Pharmaceutical and Nutraceutical segments. It offers Wafermine, a sublingual ketamine wafer, which has completed phase-2 clinical trial for the treatment of acute moderate to severe pain and complex regional pain syndrome; Xativa, a sublingual cannabidiol wafer, as well as Hypera, a tetrahydrocannabinol sublingual wafer for the treatment of anxiety, chronic pain, inflammation, and insomnia; and Wafesil and Silcap for the treatment of male erectile dysfunction.

iX Biopharma Ltd. Fundamentals Summary

How do iX Biopharma's earnings and revenue compare to its market cap?
42C fundamental statistics
Market capS$39.95m
Earnings (TTM)-S$9.59m
Revenue (TTM)S$6.06m

6.7x

P/S Ratio

-4.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
42C income statement (TTM)
RevenueS$6.06m
Cost of RevenueS$4.04m
Gross ProfitS$2.02m
Other ExpensesS$11.62m
Earnings-S$9.59m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.012
Gross Margin33.37%
Net Profit Margin-158.41%
Debt/Equity Ratio68.7%

How did 42C perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.